Taken together, our analysis establishes a reliable 13-gene panel diagnostic model and AXL gene as reliable biological markers for ccRCC, providing valuable targets and a theoretical foundation for the development of precision-targeted therapies for ccRCC. Here, AXL is linked to nonpapillary renal cell carcinoma.